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Abstract: Breast cancer research has developed rapidly in the past few decades, leading to 
longer survival times for patients and opening up the possibility of developing curative 
treatments  for  advanced  breast  cancer.  Our  increasing  knowledge  of  the  biological 
pathways associated with the progression and development of breast cancer, alongside the 
failure  of  conventional  treatments,  has  prompted  us  to  explore  gene  therapy  as  an 
alternative  therapeutic  strategy.  We  previously  reported  that  gef  gene  from  E.  coli  has 
shown considerable cytotoxic effects in breast cancer cells. However, its action mechanism 
has not been elucidated. Indirect immunofluorescence technique using flow cytometry and 
immunocytochemical analysis were used to detect breast cancer markers: estrogen (ER) 
and  progesterone  (PR)  hormonal  receptors,  human  epidermal  growth  factor  receptor-2 
proto-oncogene (c-erbB-2), ki-67 antigen and p53 protein. gef gene induces an increase in 
ER and PR expressions and a decrease in ki-67 and c-erbB-2 gene expressions, indicating a 
better prognosis and response to treatment and a longer disease-free interval and survival. It 
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also increased p53 expression, suggesting that gef-induced apoptosis is regulated by a p53-
mediated signaling pathway. These findings support the hypothesis that the gef gene offers 
a new approach to gene therapy in breast cancer. 
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1. Introduction  
Breast cancer is the most common malignant tumor and the highest cause of death by neoplasia 
among women [1]. It is correlated with multiple histopathological forms, growth rates, variations in 
metastatic  capacity  and  responses  to  hormonal  therapy.  All  of  these  variations  are  a  reflection  of 
numerous genomic modifications that take place during tumor transformation [2,3]. Uncontrolled cell 
proliferation and/or apoptosis can lead to breast cancer as a consequence of the accumulation of genetic 
lesions,  giving  rise  to  alterations  that  activate  protooncogenes  and  inactivate  tumor  suppressor  
genes [4,5]. The most significant conventional prognostic factors for breast cancer are tumor size, 
status of axillary lymph nodes, degree of differentiation and classification of the neoplasia, and a panel 
of  specific  tumor  markers  [6,7].  In  this  context,  the  most  widely  used  breast  cancer  markers  are 
estrogen (ER) and progesterone (PR) hormonal receptors, human epidermal growth factor receptor-2 
proto-oncogene  (Her-2/neu  or  c-erbB-2),  ki-67  antigen  and  p53  protein  [1,8–10].  The  prognostic 
markers ER and PR are used to select treatments with greater clinical acceptance [11,12]. ER contributes 
to the development of the most frequent five cancers in females [13]. Thus, around a third of breast 
tumors  are  ER-positive  and  are  characterized  by  slower  growth,  greater  differentiation,  a  longer 
symptom-free survival interval and a higher sensitivity to endocrine therapy with antiestrogen drugs, 
such as tamoxifen [14]. The presence of ER and PR in the same tumor increases the likelihood of a 
response to hormonal treatment [15]. 
The c-erbB-2 gene encodes a 185 kDa transmembrane glycoprotein with intrinsic tyrosine kinase 
activity related to enhanced cell growth. This proto-oncogene is overexpressed in approximately 30% 
of breast cancer patients, indicating a poor prognosis, and is associated with drug resistance [16].  
c-erbB-2 positivity has been associated with a significantly greater risk of endocrine therapy failure [15]. 
Antigen Ki-67 is a non-histone nuclear protein found in all phases of the cell cycle except for G0. 
High Ki-67 indexes are associated with low histological malignancy and with lymph node metastases [17]. 
Besides its usefulness as a cell proliferation marker, it has proven to be of prognostic value [18] in 
inverse correlation with ER receptors [19,20].  
The protein encoded by the p53 gene functions as a master regulator of cell division and apoptosis 
programs [5]. The loss of its normal function is the most common genetic alteration in all types of 
cancer, and p53 is a central protein in tumorigenesis due to its cell-cycle and apoptosis regulating 
properties. It acts as nuclear transcription factor, binding to DNA in order to regulate the transcription 
of certain genes, and it monitors the DNA integrity, preventing the division of genetically damaged 
cells [21].  
Breast  cancer  mortality  has  been  substantially  reduced  over  the  past  15  years  thanks  to  early 
detection strategies and advances in classical breast cancer therapy (surgery, chemotherapy, radiotherapy Int. J. Mol. Sci. 2011, 12                       
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and hormone therapy). However, new forms of therapy are urgently needed to improve the long-term 
survival of patients with a poor prognosis, including gene therapy. One of the most promising recently 
developments has been the introduction of suicide genes that do not require the use of a prodrug to be 
effective in tumor cells. These genes, which encode cytotoxic products, include fusogenic membrane 
proteins such as vesicular stomatitis virus (VSV) glycoprotein and gibbon ape leukaemia virus (GALV) 
envelope protein [22,23]. When these proteins are expressed in a target cell, they cause membrane 
fusions with neighboring cells, leading to the formation of large multinuclear syncytia in which cells 
finally die by apoptosis or necrosis [24]. Our group previously reported that transfection of the gef gene 
from E. coli, identified as a member of a gene family that encodes homologous cell killing function 
[25], may be a new candidate for cancer gene therapy. Using the MCF-7 breast cancer cell line, we 
developed a new MCF-7 cell line transfected with a mammalian expression vector containing the gef 
gene (MCF-7TG) under control of the mouse mammary tumor virus (MMTV) promoter. Induction of 
gef expression leads to a marked decrease in cell growth rate, cell cycle arrest, membrane blebbing, 
craters  on  cell  surface  and  cell  death  by  apoptosis  [26,27].  However,  although  the  gef  
gene has shown considerable cytotoxic effects in breast cancer cells, the action mechanism has not 
been elucidated.  
The present study demonstrates that gef gene not only reduces cell proliferation in transfected MCF-
7TG cell line but also induces alteration of the most widely utilized breast cancer prognostic markers. 
Thus,  gef  gene  induces  an  increase  in  ER  and  PR  expressions  and  a  decrease  in  Ki-67  and  
c-erbB-2  gene  expressions,  indicating  a  better  prognosis  and  response  to  treatment  and  a  longer 
disease-free  interval  and  survival.  It  also  increased  p53  expression,  suggesting  that  gef-induced 
apoptosis is regulated by a p53-mediated signaling pathway. These findings support the hypothesis that 
the gef gene offers a new approach to gene therapy in breast cancer. 
2. Results and Discussion  
Suicide gene therapy has been assayed in pre-clinical studies with various enzyme/prodrug systems, 
notably herpes simplex thymidine kinase gene (HSV-tk) [28,29]. The introduction of suicide genes that 
do not require the use of a prodrug to be effective in tumor cells, like the gef gene, represents a 
promising new development in this field [24,30,31]. The present study was designed to determine the 
mechanisms  underlying  the  considerable  cytotoxic  effects  of  the  gef  gene  in  breast  cancer  cells, 
exploring the apoptosis pathway and the ability of the gef gene to affect the degree of maturation in 
breast cancer cells by studying its effects on a panel of specific breast tumor markers. Biochemical 
tumor markers are used to establish the diagnosis, prognosis and stage of the neoplasm, to detect the 
presence of hidden metastases and recurrences and to monitor the response to treatment. In this study, 
the most widely used prognostic markers for breast cancer were selected for inclusion in a prognostic 
panel capable of predicting the clinical behavior of the tumor, including its response to an individualized 
therapeutic regimen. The panel comprised ER, PR, erbB-2, antigen ki-67 and p53 protein [9].  Int. J. Mol. Sci. 2011, 12                       
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2.1. Immunocytochemical Analysis 
The immunocytochemical study demonstrated significant modifications in the antigenic expression 
pattern of cells transfected with gef gene compared with that of control cells. Percentages of stained 
cells and intensities of staining, obtained by microscopic study of control and gef gene-induced cell 
samples, are listed in Table 1.  
Table 1. Percentages of stained cells and intensities of staining, obtained by microscopic 
study of control and gef gene-induced cells treated with dexamethasone (1 mM) for 2 or  
6 days. 
Cell line  Protein markers 
  ER  PR  c-erbB-2  Ki-67  p53 
  A  B  A  B  A  B  A  B  A  B 
MCF-7  13%  ++  20%  ++  62%  +++  72%  +++  33%  ++ 
MCF-7TG dex 2 days  50%  ++  57%  ++  27%  +  18%  ++  59%  +++
 
MCF-7TG dex 6 days  55%  ++  61%  +  17%  +  8%  +/-  55%  +++ 
A: Percentage of stained cells; B: Degree of intensity; -: negative; +: weak staining; ++: moderate 
staining; +++: intense staining. 
Results obtained showed a slight increase in the expression of ER (Figure 1) and PR (Figure 2) 
hormonal receptors and a large increase in p53 (Figure 3) expression in the MCF-7TG cell line compared 
with the parental cells. However, Ki-67 antigens (Figure 4) and c-erbB-2 oncogenes (Figure 5) showed 
a significant reduction in the MCF-7TG cell line with respect to controls.  
Figure 1. Immunocytochemical study with peroxidase staining of MCF-7 and MCF-7TG 
cells. Analysis of estrogen receptor (ER) expression in: A, parental MCF-7cells; B and C, 
MCF-7TG cells induced with dexamethasone (1 mM) for 2 and 6 days, respectively. (A, C, 
X 200 magnification; B X 400 magnification). 
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Figure 2. Immunocytochemical study with peroxidase staining of MCF-7 and MCF-7TG 
cells.  Analysis  of  progesterone  receptor  (PR)  expression  in:  (A)  parental  MCF-7cells;  
(B)  and  (C)  MCF-7TG  cells  induced  with  dexamethasone  (1  mM)  for  2  and  6  days, 
respectively. (A, C, X 200 magnification; B X 400 magnification). 
 
Figure 3. Immunocytochemical study with peroxidase staining of MCF-7 and MCF-7TG 
cells. Analysis of p53 antigen expression in: A, parental MCF-7cells; B and C, MCF-7TG 
cells induced with dexamethasone (1 mM) for 2 and 6 days, respectively, (A and C, X 400 
magnification; B, X 200 magnification). 
 
Figure 4. Immunocytochemical study with peroxidase staining of MCF-7 and MCF-7TG 
cells.  Analysis  of  Ki-67  antigen  expression  in:  A,  parental  MCF-7cells;  B  and  C, 
MCF-7TG cells induced with dexamethasone (1 mM) for 2 and 6 days, respectively. (A, C, 
X 200 magnification; B X 400 magnification). 
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Figure 5. Immunocytochemical study with peroxidase staining of MCF-7 and MCF-7TG 
cells.  Analysis  of  c-erbB-2  oncogene  expression  in: A, parental MCF-7cells; B and C, 
MCF-7TG cells induced with dexamethasone (1 mM) for 2 and 6 days, respectively. (A, X 
200 magnification; B and C, X 400 magnification) 
 
 
2.2. Indirect Immunofluorescence Analysis 
Flow cytometry results confirm those obtained by the immunocytochemical study (Figure 6) and 
were as follows: Estrogen receptor (ER): ER overexpression was observed in dexamethasone-treated 
MCF-7TG  cells  versus  parental  cells,  with  expression  in  39.22%  and  39.55%  of  MCF-7TG  cells 
treated for 2 and 6 days, respectively, compared with 10.64% of parental cells. 
Figure 6. FACScan analysis of modifications in the expression of proteins in MCF-7TG 
cells  treated  with  dexamethasone  (1  mM)  for  2  and  6  days.  The  asterisk  means  
statistically significant. 
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Progesterone Receptor (PR): PR overexpression was observed in MCF-7TG cells versus parental cells, 
with  expression  in  41.94%  and  53.6%  of  MCF-7TG  cells  treated  for  2  and  6  days,  respectively, 
compared with 13.09% of parental cells. 
 
Ki-67 Antigen: A significant reduction in Ki-67 expression was observed in MCF-7TG cells, with 
expression in 41.56% and 33.53% of MCF-7TG cells treated for 2 and 6 days, respectively, compared 
with 53.96% of parental cells. 
 
p53  Protein:  A  significant  increase  in  p53  expression  was  observed  in  MCF-7TG  cells,  with 
expression in 60.46% and 53.08% of MCF-7TG cells treated for 2 and 6 days, respectively, compared 
with 33.66% of parental cells. 
 
c-erbB-2  Oncogene:  A  significant  reduction  in  c-erbB-2  oncogene  expression  was  observed  in  
MCF-7TG cells, with expression in 26.42% and 17.97% of MCF-7TG cells treated for 2 and 6 days, 
respectively, compared with 35.37% of parental cells. 
Numerous recent studies on the value of ER and PR as prognostic markers have supported their 
clinical  relevance  [9].  IHC  procedures  are  used  to  determine  their  expressions  in  tumor  tissue  as 
indicators of the degree of proliferation, malignancy and invasion capacity of cancer cells [32]. ERs are 
intranuclear proteins, and their interaction with serum estradiol plays a key role in the regulation of 
breast  epithelium  proliferation  and  differentiation.  ER  is  clinically  relevant  because  its  presence 
identifies tumors that are sensitive to hormone treatment with the corresponding antagonist. Thus, 
around half of metastatic breast cancers expressing ER and/or PR respond to endocrine therapy, and 
postoperative adjuvant endocrine therapy reduces the risk of recurrence by around 50% [15]. The role 
of PR is well documented, and it is widely accepted that ER+PR– patients have a more aggressive 
subtype of breast cancer with a poor prognosis, which may be related to a worse response to endocrine 
treatment [33,34]. In general, the presence of these hormonal receptors in breast carcinoma predicts a 
longer disease-free interval and survival [35]. Our demonstration that gef gene expression produces an 
increase in ER and PR levels implies a better response of these cells to hormonal treatment, since 
recurrence and survival rates are worse in ER- and PR-negative patients [34]. 
Various studies have demonstrated that 25–30% of all breast cancers overexpress c-erbB-2 and that 
these tumors show higher tumor cell growth rates and more rapid progression to metastases versus 
tumors without overexpression of this oncogene [36,37]. c-erbB-2 in breast carcinoma predicts time to 
recurrence, and its presence, in association with lower ER and PR levels and higher KI-67 levels, has 
been  related  to  a  lower  responsiveness  to  endocrine  therapy  [15].  Its  amplification  is  one  of  
the  most  common  genetic  alterations  associated  with  breast  cancer,  giving  rise  to  resistance  to 
chemotherapeutic drugs and to more aggressive clinicopathological behaviors [38]. Our finding of a 
progressive  decrease  in  the  expression  of  oncogene  c-erbB-2  induced  by  gef  in  MCF-7TG  cells 
indicates a better prognosis, since tumors overexpressing this oncogene have higher tumor cell growth 
and invasive potential versus those without this overexpression [36,37].  
Expression of Ki-67 was also reduced in the MCF-7TG cells. This antigen is overexpressed in G1 
and S phases but absent in resting cells and is used to estimate the intensity of proliferation. Ki-67 Int. J. Mol. Sci. 2011, 12                       
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expression is considered of prognostic and diagnostic value in breast cancer as a cell proliferation 
marker [39,40]. When expressed in breast carcinoma, Ki-67 indicates tumor proliferation and therefore a 
poor  prognosis.  Hence,  the  reduced  Ki-67  expression  in  MCF-7TG  cells  appears  to  support  the 
antiproliferative effect of gef gene in breast cancer cells [26,27], although the relationship between 
expression of this antigen and metastatic capacity is controversial [41]. 
Our  immunocytochemical  study  showed  that  the  p53  tumor  suppressor  gene  was  significantly  
up-regulated by induction of gef gene. The p53 gene intervenes in the cell cycle, negatively regulating 
tumor growth, and its overexpression is known to be induced by DNA damage, producing cell arrest in 
G1 phase for repair or entry into apoptosis [5]. Numerous studies have addressed the prognostic or 
predictive significance of p53 in breast carcinomas but controversial results have been published [42–44]. 
Most  clinicopathological  studies  have  used  IHC  techniques  to  estimate  p53  accumulation,  some 
affirming [45,46] and others refuting [47,48] the predictive value of p53, which may be of critical 
importance  for  breast  carcinoma  treatment,  especially  chemotherapy.  Studies  on  the  prognostic 
significance of p53 mutation found it to be a significant independent negative factor for disease-free 
and/or overall survival [7,49]. The effects of p53 on cell growth, arrest and apoptosis and on the 
maintenance of genomic integrity are highly complex. The effects of distinct p53 mutations are likely 
to differ in their influence on tumor development, growth and prognosis [50]. Mutation of the gene, 
with IHC-detectable protein accumulation in cancer cells, is associated with a poor prognosis in breast 
cancer.  It  is  correlated  with  an  absence  of hormone receptors, presence of receptor for Epidermal 
Growth Factor (EGF) and a more aggressive tumor [51]. However, the p53 overexpression detected by 
IHC  is  not  always  related  to  p53  gene  mutations  [52].  It  also  detects  accumulation  of  wild-type  
p53  [53],  whose  accumulation  is  frequently  observed  in  normal  tissues  and  benign  neoplasms  in 
response to a specific cell cycle phase or to spontaneous genetic errors or microenvironmental stresses 
on individual cells. The p53-encoded protein participates in the apoptotic pathway by inducing cell 
cycle arrest and initiating apoptosis, which were previously reported as anti-cancer effects of gef gene 
expression on the MCF-7 cell line [26,27]. However, the mechanism of action has not been elucidated. 
The present finding of a significant upregulation of p53 gene suggests that gef-induced apoptosis is 
regulated  by  a  p53-mediated  signaling  pathway.  Our  results  are  similar  to  those  obtained  by  
Seo et al., [54] after treatment of the same breast cancer line with PEGylated conjugated linoleic acid.  
3. Experimental Section  
3.1. Cell Lines and Culture Conditions 
The human breast cancer MCF-7 cell line was kindly provided by Mr. N. Olea of the Sánchez Mora 
Tumour Biology Institute, San Cecilio University Hospital of Granada. MCF-7 cells were grown at  
37  °C  in  an  atmosphere  containing  5%  CO2,  with  Dulbecco’s  modified  Eagle  Medium  (DMEM) 
(Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated foetal bovine serum (FBS) 
(Gibco),  2%  L-glutamine,  2.7%  sodium  bicarbonate,  1%  Hepes  buffer,  40  mg/L  gentamicin  and  
500 mg/L ampicillin. 
Human breast cancer MCF-7TG cells were obtained by transfection of MCF-7 cell line with gef 
gene as we describe in previous work [26].
 Int. J. Mol. Sci. 2011, 12                       
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3.2. Immunocytochemical Analysis 
Adherent parental MCF-7 cells and MCF-7TG cells treated with dexamethasone for 48 h and 96 h 
were harvested with PBS-EDTA (0.02%), washed twice with PBS at 1500 rpm for 5 min at 4 °C, and 
resuspended in 0.5 mL of PBS. These cells were fixed to slides by high-speed centrifugation, and the 
slides were subsequently dried in room air, fixed for 60 seconds with 70% methanol, and frozen to 
−20  °C.  The  immunocytochemical  analysis  was  done  using  ChemMate  Kit  (Dako)  according  to 
manufacturer’s  instructions.  The  slides  were  thawed,  washed  with  PBS,  incubated  in  peroxidase-
inhibition solution for 5 min. They were then washed in PBS three times, and after that incubated with 
primary antibody (see below) for 1 h in a dark humid chamber. Next, they were washed with PBS three 
times, incubated with secondary antibody (AB2) for 30 min in a dark humid chamber, and washed 
again three times with PBS. The slides were incubated with conjugated antibody for 25 min, washed 
twice,  first  with  PBS  and  then  with  water,  and  developed  with  diaminobenzidine  (DAB)  until 
appearance under microscope of the desired staining. Once stained, slides were washed three times 
with distilled water and then in rising concentrations of ethanol (from water to 96% ethanol). Readings 
were done under optical microscope and interpreted by the same observer. The antibodies used are 
listed in Table 2. 
Table 2. Antibodies used in the Immunocytochemical and Indirect Immunofluorescence analysis. 
Antibody  Source  Dilution  Staining pattern in cancer cells 
ER  Dako (Barcelona, Spain)  1:200  Nuclear staining 
PR  Dako (Barcelona, Spain)  1:250  Nuclear staining 
c-erbB-2  Dako (Barcelona, Spain)  1:250  Membrane staining 
Ki-67  Dako (Barcelona, Spain)  1:100  Nuclear staining 
p53  Dako (Barcelona, Spain)  1:100  Nuclear and Cytoplasm staining 
3.3. Indirect Immunofluorescence Analysis 
The gef gene was induced in MCF-7TG cells with dexamethasone for 48 or 96 h. Parental MCF-7 
cells  with  or  without  dexamethasone  incubation  were  used  as  controls.  Cells  were  harvested  in  
PBS-EDTA (0.02%), washed twice in cold PBS, counted and pelleted by centrifugation at 1500 rpm 
for 5 min at 4 °C, and 6 × 10
5 cells were incubated with 10% (w/v) foetal calf serum in PBS for 15 min 
to block non-specific antibody binding. Then, pellets were resuspended in 20 µL of the monoclonal 
antibody. The resulting solution was shaken and incubated for 30 min in the dark at 4 °C. Then, after 
being washed once with cold PBS and centrifuged at 1500 rpm for 5 min, the supernatant was removed 
and 15 µL of fluorescein-conjugated antiimmunoglobulin (Sigma, St. Louis, MO) diluted to 1:5 or 
1:10 was added to the pellets. They were resuspended and incubated for 30 min at 4 °C and, after two 
washes with cold PBS, the supernatant was decanted and cells were fixed with 70% ethanol. Cells 
were  then  processed  using  a  FACScan  flow  cytometer  (Becton  Dickinson,  San  Jose,  USA).  The 
antibodies used are listed in Table 2. 
The  final  expression  of  the  specific  fluorescence  for  each  antibody  was  corrected  for 
autofluorescence and non-specific fluorescence. All experiments were performed in quadruplicate and 
yielded similar results. Int. J. Mol. Sci. 2011, 12                       
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3.4. Statistical Analysis 
SPSS version 7.5 [55] was used for the statistical analysis. The results were compared by means of 
the Student’s t test. All data are expressed as means ± SD. Differences were considered statistically 
significant at a P value of < 0.05.  
4. Conclusions 
Induction of gef gene expression in breast cancer cells produced changes in specific tumor markers 
that indicated a better prognosis and response to treatment, with an increase in the disease-free interval 
and survival rate. Thus, c-erbB-2 and Ki-67 expressions were lower in gef gene-transfected MCF-7 
breast cancer cells, predicting a reduced proliferation rate and metastasizing capacity, and ER and PR 
expressions were higher, predicting a better response to hormonal treatment. Finally, the upregulation 
of p53 in MCF-7TG cells suggests that gef-induced apoptosis is regulated by a p53-mediated signaling 
pathway.  Overall,  the  anti-cancer  effects  of  gef  gene  on  MCF-7  breast  cancer  cells  may  be  of 
therapeutic value. We are currently working on experiments to enhance gef gene activity by specific 
enhancer/promoter genes (such as tyrosinase) to induce tissue-specific expression. The possibility of 
using selective transcriptional control sequences with gef therefore offers the gene therapist a tool of 
significant potential in which the use of a prodrug is not necessary.  
Acknowledgements 
The study was supported in part by grants from the Science and Innovation Ministry through the 
project  REF:  SAF2009-12295,  the  Instituto  de  Salud  Carlos  III  (Fondo  de  Investigación  Sanitaria 
project n°. PI10/02295 and by GREIB start-up project for young researchers (GREIB.PYR_2011_05). 
References  
1.  Marasà,  S.;  Sciancalepore,  G.;  Marasà,  L.  Breast  cancer  less  than  1  cm:  Bio-morphologic 
characterization with ER, PgR, Ki67, Her-2/Neu, MDV, MAGS, p53, EGF-R. Pathologica 2008, 
100, 156–161.  
2.  Jovanovic, J.; Rønneberg, J.A.; Tost, J.; Kristensen, V. The epigenetics of breast cancer. Mol. 
Oncol. 2010, 4, 242–254.  
3.  Kurdistani, S.K. Histone modifications in cancer biology and prognosis. Prog. Drug Res. 2011, 67, 
91–106.  
4.  Lee, E.Y.; Muller, W.J. Oncogenes and tumor suppressor genes. Cold Spring Harb. Perspect. Biol. 
2010, 2, doi:10.1101/cshperspect.a003236.  
5.  Green, D.R.; Kroemer, G. Cytoplasmic functions of the tumor suppressor p53. Nature 2009, 458, 
1127–1130. 
6.  Fisher,  E.R.;  Constantino,  J.;  Fisher,  B.;  Redmond,  C.  Pathologic  findings  from  the  national 
surgical adjuvant breast project (Protocol 4). Cancer 1993, 71, 2141–2150. 
7.  Kröger,  N.;  Milde-Langosch,  K.;  Riethdorf,  S.;  Schmoor,  C.;  Schumacher,  M.;  Zander,  A.R.; 
Löning, T. Prognostic and predictive effects of immunohistochemical factors in high-risk primary 
breast cancer patients. Clin. Cancer Res. 2006, 12, 159–168. Int. J. Mol. Sci. 2011, 12                       
 
 
7455
8.  Bostrom,  P.;  Soderstrom,  M.;  Vahlberg,  T.;  Soderstrom,  K.O.;  Roberts,  P.J.;  Carpen,  O.; 
Hirsimaki,  P. MMP-1 expression has an independent prognostic value in breast cancer. BMC 
Cancer 2011, 11, doi:10.1186/1471-2407-11-348. 
9.  Ross, J.S.; Christos hatzis, W.; Symmans, F.; Lajos, G. Commercialized multigene predictors of 
clinical outcome for breast cancer. Oncologist 2008, 13, 477–493. 
10.  Malamou-Mitsi,  V.;  Gogas,  H.;  Dafni,  U.;  Bourli,  A.;  Fillipides,  T.;  Sotiropoulou,  M.; 
Vlachodimitropoulos,  D.;  Papadopoulos,  S.,  Tzaida,  O.;  Kafiri,  G.;  et  al.  Evaluation  of  the 
prognostic  and  predictive  value  of  p53  and  Bcl-2  in  breast  cancer  patients  participating  in  a 
randomized  study  with  dose-dense  sequential  adjuvant  chemotherapy.  Ann.  Oncol.  2006,  17, 
1504–1511. 
11.  Ross,  J.S.;  Symmans,  W.F;  Pusztai,  L.;  Hortobagyi,  G.N.  Standardizing  slide-based  assays  in 
breast cancer: Hormone receptors, HER2, and sentinel lymph nodes. Clin. Cancer Res. 2007, 13, 
2831–2835. 
12.  Ring, B.Z.; Seitz, R.S.; Beck, R.; Shasteen, W.J.; Tarr, S.M.; Cheang, M.C.; Yoder, B.J.; Budd, G.T.; 
Nielsen, T.O.; Hicks, D.G.; et al. Novel prognostic immunohistochemical biomarker panel for 
estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24, 3039–3047. 
13.  Service, R.F. New role for estrogen in cancer? Science 1998, 279, 1631–1633. 
14.  Osborne,  C.K.  Tamoxifen  in  the  treatment  of  breast  cancer.  N.  Engl.  J.  Med.  1998,  339,  
1609–1618. 
15.  Rastelli,  F.;  Crispino,  S.  Factors  predictive  of  response  to  hormone  therapy  in  breast  cancer. 
Tumori 2008, 94, 370–383. 
16.  Mendelson, J.; Baselga, J. Status of epidermal growth factor receptor antagonist in biology and 
treatment of cancer. J. Clin. Oncol. 2003, 21, 2787–2799. 
17.  Jeziorski, A.; Blonski, J.Z.; Niewiadomska, H. The expression of products of oncogens c-erbB-2 
and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female 
breast. J. Exp. Clin. Cancer Res. 2000, 19, 61–67. 
18.  Dowsett, M.; Smith, I.E.; Ebbs, S.R.; Dixon, J.M.; Skene, A.; A’Hern, R.; Salter, J.; Detre, S.; 
Hills, M.; Walsh, G. Prognostic value of Ki67 expression after short-term presurgical endocrine 
therapy for primary breast cancer. J. Natl. Cancer Inst. 2007, 99, 167–170. 
19.  Kerlikowske, K.; Molinaro, A.M.; Gauthier, M.L.; Berman, H.K.; Waldman, F.; Bennington, J.; 
Sanchez,  H.;  Jimenez,  C.;  Stewart,  K.;  Chew,  K.;  et  al.  Biomarker  expression  and  risk  of 
subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl. Cancer Inst. 2010, 102, 
627–637.  
20.  Cheang, M.C.; Chia, S.K.; Voduc, D.; Gao, D.; Leung, S.; Snider, J.; Watson, M.; Davies, S.; 
Bernard, P.S.; Parker, J.S.; et al. Ki67 index, HER2 status, and prognosis of patients with luminal 
B breast cancer. J. Natl. Cancer Int. 2009, 101, 736–750.  
21.  Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. 
Nat. Rev. Mol. Cell Biol. 2008, 9, 402–412. 
22.  Diaz,  R.M.;  Bateman,  A.;  Emiliusen,  L.;  Fielding,  A.;  Trono,  D.;  Russell,  S.J.;  Vile
  R.G.  
A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 2000, 
7, 1656–1663.  Int. J. Mol. Sci. 2011, 12                       
 
 
7456
23.  Kirkham, L.A.; Bateman, A.R.; Melcher, A.A.; Vile, R.G.; Fielding, A.K. Lack of specificity of 
cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope 
glycoprotein. J. Gene Med. 2002, 4, 592–600. 
24.  Bateman, A.R.; Harrington, K.J.; Kottke, T.; Ahmed, A.; Melcher, A.A.; Gough, M.J.; Linardakis, 
E.; Riddle, D.; Dietz, A.; Lohse, C.M.; et al. Viral fusogenic membrane glycoproteins kill solid 
tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by 
dendritic cells. Cancer Res. 2002, 62, 6566–6578. 
25.  Gerdes, K.; Poulsen, L.K.; Thisted, T.; Nielsen, A.; Anderssen, P.H. The hok killer gene family in 
Gram negative bacteria. New Biol. 1990, 2, 964–956.  
26.  Boulaiz,  H.;  Prados,  J.;  Melguizo,  C.;  Garcia,  A.;  Marchal,  J.A.;  Carrillo,  E.;  Vélez  C.;  
Aranega, A. Inhibition of cell proliferation and apoptosis induction in human melanoma MCF7 
cell line by gef gene. Br. J. Cancer 2003, 89, 192–198. 
27.  Boulaiz,  H.;  Prados,  J.;  Marchal,  J.A.;  Concha,  A.;  Melguizo,  C.;  Carrillo,  E.;  Vélez,  C.;  
Martínez, A.; Aránega, A. Modification of Ki-67 antigen and Cell surface changes during gef gene 
induced apoptosis in human breast cancer MCF-7 cells. Cell Mol. Biol. 2005, 51, 87–92. 
28.  Schepelmann,  S.;  Springer,  C.J.  Viral  vectors  for  gene-directed  enzyme  prodrug  therapy.  
Curr. Gene Ther. 2006, 6, 647–670. 
29.  Ladd, B.; O'Konek, J.J.; Ostruszka, L.J.; Shewach, D.S. Unrepairable DNA double-strand breaks 
initiate cytotoxicity with HSV-TK/ganciclovir. Cancer Gene Ther. 2011, 51, 751–759. 
30.  Zarovni, N.; Vago, R.; Solda, T.; Monaco, L.; Fabbrini, M.S. Saporin as a novel suicide gene in 
anticancer gene therapy. Cancer Gene Ther. 2006, 1, 1–9. 
31.  Rama,  A.R.;  Prados,  J.;  Melguizo,  C.;  Burgos,  M.;  Alvarez,  P.J.;  Rodriguez-Serrano,  F.;  
Ramos,  J.L.;  Aranega,  A.  Synergistic  antitumoral  effect  of  combination  E  gene  therapy  and 
Doxorubicin in MCF-7 breast cancer cells. Biomed. Pharmacother. 2011, 65, 260–270. 
32.  Rosen, P.P.; Lesser, M.L.; Arroyo, C.D.; Cranor, M.; Borgen, P.; Norton, L. P53 in node negative 
breast  carcinoma:  An  immunohistochemical study of epidemiological risk factors, histological 
features and prognosis. J. Clin. Oncol. 1995, 13, 821–830. 
33.  Arpino, G.; Weiss, H.; Lee, A.V.; Schiff, R.; de Placido S.; Osborne, C.K. Estrogen receptor-
positive, progesterone receptor-negative breast cancer: Association with growth factor receptor 
expression and tamoxifen resistance. J. Natl. Cancer Inst. 2005, 9, 71254–1261. 
34.  Ciccarese, M.; Vito, L.; de Laurentis, M. Controversies in adjuvant endocrine therapy for pre- and 
post-menopausal women with breast cancer. Eur. J. Cancer 2008, 6, 4–9. 
35.  Mansour, E.G.; Ravdin, Y.; Dressler, L. Prognostic factors in early breast carcinoma. Cancer 1994, 
74, 381–400. 
36.  Agrup, M.; Stal, O.; Olsen, K.;Wingren, S. C-erbB-2 overexpression and survival in early onset 
breast cancer. Breast Cancer Res. Treat. 2000, 63, 23–29. 
37.  Leong, A.S.-Y. Immunohistological markers for tumor prognostication. Curr. Diag. Pathol. 2001, 
7, 176–186. 
38.  Sahin,  A.A.  Biologic  and  clinical  significance  of  HER-2/neu  (c-  erbB-2)  in  breast  cancer.  
Adv. Anat. Pathol. 2000, 7, 158–166. Int. J. Mol. Sci. 2011, 12                       
 
 
7457
39.  Ross, J.; Linette, G.; Stec, J.; Clark, E.; Ayers, M.; Leschly, N.; Symmans, W.F.; Hortobagyi G.N.; 
Pusztai, L. Breast cancer biomarkers and molecular medicine. Expert. Rev. Mol. Diagn. 2003, 3, 
573–585. 
40.  Van Diest, P.J.; van de Wall, E.; Baak, J.P. Prognostic value of proliferation in invasive breast 
cancer: A review. J. Clin. Pathol. 2004, 57, 675–681. 
41.  Bubb, R.S.; Komaki, R.; Hachiya, T.; Milas, I.; Ro, J.Y.; Langford, L.; Sawaya, R.; Putnam, J.B.; 
Allen,  P.;  Cox,  J.D.;  et  al.  Association  of  Ki-67,  p53,  and  bcl-2  expression  of  the  primary  
non-small-cell lung cancer lesion with brain metastatic lesion. Int. J. Rad. Oncol. Biol. Phys. 2002, 
53, 1216–1224. 
42.  Barbareschi,  M.  Prognostic  value  of  the  immunohistochemical  expression  of  p53  in  breast 
carcinomas. Apll. Imunohistochem. 1996, 4, 106–116. 
43.  Allred, D.C.; Harvey, J.M.; Berardo, M.; Gary, M.; Clark, G.M. Prognostic and predictive factors 
in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11, 155–168. 
44.  Bankfalvi, A.; Tory, K.; Kemper, M.; Breukelmann, D.; Cubick, C.; Poremba, C.; Füzesi, L.; 
Lellè, R.J.; Böcker, W. Clinical relevance of immunohistochemical expression of p53-targeted 
gene products mdm-2, p21 and Bcl-2 in breast carcinoma. Pathol. Res. Pract. 2000, 196, 489–501. 
45.  Bottini,  A.;  Berruti,  A.;  Bersiga,  A.;  Brizzi,  M.P.;  Brunelli,  A.;  Gorzegno,  G.;  DiMarco,  B.; 
Aguggini, S.; Bolsi, G.; Cirillo, F.; et al. p53 but not Bcl-2 immunostaining is predictive of poor 
clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 
2000, 6, 2751–2758. 
46.  Clahsen, P.C.; van de Velde, C.J.; Duval, C.; Pallud, C.; Mandard, A.M.; Delobelle-Deroide, A.; 
van den Broek, L.; Sahmoud, T.M.; van de Vijver, M.J. p53 protein accumulation and response to 
adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. 
Oncol. 1998, 16, 470–479. 
47.  Rozan,  S.;  Vincent-Salomon,  A.;  Zafrani,  B.;  Validire,  P.;  de  Cremoux,  P.;  Bernoux,  A.; 
Nieruchalski, M.; Fourquet, A.; Clough, K.; Dieras, V.; et al. No significant predictive value of  
c-erbB-2 or p53 expression regarding sensitivy to primary chemotherapy or radiotherapy in breast 
cancer. Int. J. Cancer 1998, 79, 27–33. 
48.  Sjöström, J.; Blomqvist, C.; Heikkilävon, P.; von Boguslawski, P.K.; Räisänen-Sokolowski, A.; 
Bengtsson, N.O.; Mjaaland, I.; Malmström, P.; Ostenstadt, B.; Bergh, J.; et al. Predictive value of 
p53, mdm-2, p21, and mib-1 for chemotherapy response. Clin. Cancer Res. 2000, 6, 3103–3110. 
49.  Falette, M.P.; Paperin, I.; Treilleux, A.C.; Gratadour, N.; Peloux, H.; Mignotte, N.; Tooke, E.; 
Löfman, M.; Inganäs, M.; Bremond, A.; et al. Prognostic value of p53 gene mutations in a large 
series of node-negative breast cancer patients. Cancer Res. 1998, 58, 1451–1455. 
50.  Dai, C.; Gu, W. p53 post-translational modification: Deregulated in tumorigenesis. Trends Mol. 
Med. 2010, 16, 528–536. 
51.  Gentile, M.; Bergman Jungeström, M.; Olsen, K.E.; Söderkvist P.; Wingren, S. p53 and survival 
in  early  onset  breast  cancer:  Analysis  of  gene  mutations,  loss  of  heterozygosity  and  protein 
accumulation. Eur. J. Cancer 1999, 35, 1202–1207. 
52.  Blagosklonny,  M.V.  Loss  of  function  and  p53  protein  stabilization.  Oncogene  1997,  15,  
1889–1893. Int. J. Mol. Sci. 2011, 12                       
 
 
7458
53.  Vagunda,  V.;  Smardová,  J.;  Vagundová,  M.;  Jandáková,  E.;  Zaloudík,  J.;  Koukalová,  H. 
Correlations  of  breast  carcinoma  biomarkers  and  p53  tested  by  FASAY  and 
immunohistochemistry. Pathol. Res. Pract. 2003, 199, 795–801. 
54.  Seo,  J.H.;  Moon,  H.S.;  Kim,  I.Y.;  Guo,  D.D.;  Lee,  H.G.;  Choi,  Y.J.;  Cho,  C.S.  PEGylated 
conjugated linoleic acid stimulation of apoptosis via a p53-mediated signaling pathway in MCF-7 
breast cancer cells. Eur. J. Pharm. Biopharm. 2008, 70, 621–626. 
55.  SPSS, version 7.5; SPSS: Chicago, IL, USA, 1997. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 